Squamous Cell Carcinoma Of The Head And Neck – Landscape & Forecast – Disease Landscape & Forecast
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic SCCHN. For nearly a decade, the EGFR inhibitor Erbitux (Eli Lilly / Merck KGaA) was the cornerstone in the treatment algorithm. Immune checkpoint inhibitors (e.g., Keytruda, Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo) are also prescribed in later lines, where competition is fierce. Although SCCHN has historically been a complex challenge for drug developers, many immuno-oncology treatment approaches and other drug classes are in the late-phase pipeline for both metastatic and early-stage settings. Several agents are positioned to treat the untapped and lucrative locoregionally advanced SCCHN, fueling market growth over the 2021-2031 forecast period.
Questions answered
- What is the current treatment algorithm for locoregionally advanced and recurrent or metastatic SCCHN in the major pharmaceutical markets? What are interviewed experts’ views on current and emerging late-phase therapies?
- How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over the 2021-2031 forecast period?
- What market and patient share can agents in late-phase development for SCCHN expect to secure?
- What are the key drivers of and constraints on the SCCHN therapy market, and how will these factors change over the 10-year forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2023 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Squamous Cell Carcinoma Of The Head And Neck - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- SCCHN - Key findings
- Key updates
- April 2023
- Q4 2022
- December 2022
- Q3 2022
- September 2022
- August 2022
- Q2 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Market outlook
- Key findings
- Major-market share of SCCHN drug classes in 2021
- Major-market share of SCCHN drug classes in 2031
- Drug-treatable population share and major-market sales share in SCCHN in 2021
- Drug-treatable population share and major-market sales share in SCCHN in 2031
- Population positioning of therapies in SCCHN
- SCCHN SWOT analysis
- Market drivers and constraints
- What factors are driving the market for SCCHN?
- What factors are constraining the market for SCCHN?
- Major-market sales for SCCHN by region: 2021-2031
- Major-market sales for SCCHN by drug class: 2021-2031
- Major-market sales of key therapies for SCCHN: 2021-2031
- Segment-specific trends
- Patient-share dynamics of key treatments for locoregionally advanced non-nasopharyngeal SCCHN in the United States: 2021-2031
- Major-market shares of drug classes for locoregionally advanced non-nasopharyngeal SCCHN: 2021-2031
- Patient-share dynamics of key treatments for first-line non-nasopharyngeal SCCHN in the United States: 2021-2031
- Patient-share dynamics of key treatments for first-line nasopharyngeal SCCHN in the United States: 2021-2031
- Major-market shares of drug classes for first-line non-nasopharyngeal SCCHN: 2021-2031
- Major-market shares of drug classes for first-line nasopharyngeal SCCHN: 2021-2031
- Patient-share dynamics of key treatments for second-line non-nasopharyngeal SCCHN in the United States: 2021-2031
- Patient-share dynamics of key treatments for second-line nasopharyngeal SCCHN in the United States: 2021-2031
- Patient share dynamics of key therapies in third-line non-nasopharyngeal SCCHN in the United States: 2021-2031
- Patient share dynamics of key therapies in third-line nasopharyngeal SCCHN in the United States: 2021-2031
- Major-market shares of drug classes for second-line non-nasopharyngeal SCCHN: 2021-2031
- Major-market shares of drug classes for third-line non-nasopharyngeal SCCHN: 2021-2031
- Major-market shares of drug classes for second-line nasopharyngeal SCCHN: 2021-2031
- Major-market shares of drug classes for third-line nasopharyngeal SCCHN: 2021-2031
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Anatomy, development, and progression of SCCHN
- Anatomy, development, and progression of SCCHN
- Risk factors associated with SCCHN
- Risk factors associated with SCCHN
- Staging and classification
- Clinical staging of SCCHN
- Definition of TNM staging classification for oral cavity SCCHN
- Definition of TNM staging classification of hypopharyngeal SCCHN
- Definition of TNM staging classification of laryngeal SCCHN
- TNM staging system for classification of oral cavity, hypopharyngeal, and laryngeal SCCHN
- Definition of TNM staging classification for oropharyngeal SCCHN
- TNM staging system for the classification of oropharyngeal SCCHN
- Definition of TNM staging classification of nasopharyngeal SCCHN
- TNM staging system for classification of nasopharyngeal SCCHN
- Composite TNM staging and treatment overview of SCCHN
- Key pathways and drug targets
- Key pathways and drug targets in SCCHN
- Immune checkpoint activation and pathways
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of squamous cell carcinoma of the head and neck
- Diagnosed incident cases of squamous cell carcinoma of the head and neck: 2021-2031
- Diagnosed incident cases of squamous cell carcinoma of the head and neck by site (nasopharyngeal vs. non-nasopharyngeal): 2021-2031
- Disease definition
- Methods
- Sources used for stage distribution of squamous cell carcinoma of the head and neck
- Diagnosed incident cases of nasopharyngeal squamous cell carcinoma of the head and neck by stage: 2021-2031ttttt
- Diagnosed incident cases of non-nasopharyngeal squamous cell carcinoma of the head and neck by stage: 2021-2031ttt
- Disease definition
- Methods
- Sources used for metastatic recurrent incident cases of squamous cell carcinoma of the head and neck
- Metastatic recurrent incident cases of squamous cell carcinoma of the head and neck: 2021-2031
- SCCHN patient flow
- Sources used for drug-treatable populations of SCCHN
- Drug-treatable cases of SCCHN (all histologies): 2021-2031
- Drug-treatable cases of non-nasopharyngeal SCCHN: 2021-2031
- Drug-treatable cases of nasopharyngeal SCCHN: 2021-2031
- Sources used for drug-treated SCCHN populations
- Drug-treated cases of SCCHN (all histologies): 2021-2031
- Drug-treated cases of non-nasopharyngeal SCCHN: 2021-2031
- Drug-treated cases of nasopharyngeal SCCHN: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for SCCHN
- Key current therapies
- Overview
- Current treatments used for SCCHN
- Recent market events influencing the use of key current therapies in SCCHN
- Mechanism of action of key current drugs used for SCCHN
- Key results from select clinical trials investigating Erbitux for the treatment of SCCHN
- Ongoing clinical development of Erbitux
- Key ongoing clinical trials of Erbitux in the treatment of SCCHN
- Expert insight: Erbitux
- Key results from select clinical trials investigating Keytruda for the treatment of SCCHN
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of SCCHN
- Expert insight: Keytruda
- Key results from select clinical trials investigating Opdivo for SCCHN
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of SCCHN
- Expert insight: Opdivo
- Key results from select clinical trials investigating Steboronine for the treatment of SCCHN
- Ongoing clinical development of Steboronine
- Expert insight: Steboronine
- Key results from select clinical trials investigating Akalux for the treatment of SCCHN
- Ongoing clinical development of Akalux
- Key ongoing clinical trials of Akalux in the treatment of SCCHN
- Expert insight: Akalux
- Medical practice
- Early-stage localized (stage I/II) SCCHN
- Locoregionally advanced (stage III/IVA/IVB) SCCHN
- First-line recurrent or metastatic SCCHN
- Second- and third-line recurrent or metastatic SCCHN
- Treatment guidelines
- Patient characteristics influencing drug selection in SCCHN
- Treatment decision tree for early-stage localized (stage I/II) SCCHN
- Treatment decision tree for locoregionally advanced (stage III/IVA/IVB) SCCHN
- Treatment decision tree for recurrent or metastatic SCCHN
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in SCCHN
- Top unmet needs in SCCHN: current and future attainment
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for SCCHN
- Estimated market authorization dates of key emerging therapies for the treatment of SCCHN
- Key results from select clinical trials investigating Yervoy for the treatment of SCCHN
- Analysis of clinical development program for Yervoy
- Key ongoing clinical trials of Yervoy in the treatment of SCCHN
- Expectations for market authorization and sales opportunity of Yervoy in SCCHN
- Key results from select clinical trials investigating Tecentriq for the treatment of SCCHN
- Analysis of clinical development program for Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of SCCHN
- Expert insights: Tecentriq
- Expectations for the market authorization and sales opportunity of Tecentriq in SCCHN
- Key results from select clinical trials investigating toripalimab for the treatment of SCCHN
- Analysis of clinical development program for toripalimab
- Key ongoing clinical trials of toripalimab in the treatment of SCCHN
- Expert insight: toripalimab
- Expectations for the market authorization and sales opportunity of toripalimab in SCCHN
- Key results from select clinical trials investigating penpulimab for the treatment of SCCHN
- Analysis of the clinical development program for penpulimab
- Key ongoing clinical trials of penpulimab in the treatment of SCCHN
- Expectations for the market authorization and sales opportunity of penpulimab in SCCHN
- Key results from select clinical trials investigating rovaleucel for the treatment of SCCHN
- Analysis of the clinical development program for rovaleucel
- Expert insight: rovaleucel
- Expectations for the market authorization and sales opportunity of rovaleucel in SCCHN
- Key results from select clinical trials investigating Multikine for the treatment of SCCHN
- Analysis of the clinical development program for Multikine
- Expert insight: Multikine
- Expectations for the market authorization and sales opportunity of Multikine in SCCHN
- Key results from select clinical trials investigating Lenvima for the treatment of SCCHN
- Analysis of the clinical development program for Lenvima
- Key ongoing clinical trials of Lenvima in the treatment of SCCHN
- Expert insight: Lenvima
- Expectations for the market authorization and sales opportunity of Lenvima in SCCHN
- Key results from select clinical trials investigating xevinapant for the treatment of SCCHN
- Analysis of the clinical development program for xevinapant
- Key ongoing clinical trials of xevinapant in the treatment of SCCHN
- Expert insight: xevinapant
- Expectations for market authorization and sales opportunity of xevinapant in SCCHN
- Key results from select clinical trials investigating buparlisib for the treatment of SCCHN
- Analysis of the clinical development program for buparlisib
- Key ongoing clinical trials of buparlisib in the treatment of SCCHN
- Expert insight: buparlisib
- Expectations for market authorization and sales opportunity of buparlisib in SCCHN
- Key results from select clinical trials investigating tipifarnib for the treatment of SCCHN
- Analysis of the clinical development program for tipifarnib
- Key ongoing clinical trials of tipifarnib in the treatment of SCCHN
- Expert insight: tipifarnib
- Expectation for market authorization and sales opportunity of tipifarnib in SCCHN
- Early-phase pipeline analysis
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in SCCHN: United States
- General reimbursement environment: United States
- Key market access considerations in SCCHN: EU5
- General reimbursement environment: EU5
- Key market access considerations in SCCHN: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Squamous cell carcinoma of the head and neck bibliography
- Abbreviations
- Key findings
Catherine E. Willoughby, Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Willoughby has more than 10 years of experience in oncology research and drug discovery. She obtained her Ph.D. at Newcastle University, where she explored novel therapeutic strategies to treat liver cancer. She was a Sara Borrell Postdoctoral Fellow at IDIBAPS-Hospital Clinic, where she investigated new treatment combinations to overcome resistance to immune checkpoint inhibitors, and more recently a postdoctoral fellow at IRB Barcelona, where she investigated molecular glue therapeutics to treat immune-inflammatory skin diseases. Dr. Willoughby also holds a B.Sc. (Honors) in medical biochemistry with industrial experience from the University of Manchester and an M.Res. in cancer research from Newcastle University.